HDAC6 and lung carcinoma: Further, C15:0 has a strong dose-dependent antiproliferative effect on multiple cancer cell types, including human breast cancer (MCF-7, MDA-MB-231), lung cancer (A549), pancreatic cancer (PANC-1), and liver cancer (HepG2) cells, which have been attributed to JAK2/STAT3 and HDAC6-inhibiting C15:0 activities [24,26].